CN119136831A - 长效粒细胞巨噬细胞-集落刺激因子 - Google Patents

长效粒细胞巨噬细胞-集落刺激因子 Download PDF

Info

Publication number
CN119136831A
CN119136831A CN202380037559.9A CN202380037559A CN119136831A CN 119136831 A CN119136831 A CN 119136831A CN 202380037559 A CN202380037559 A CN 202380037559A CN 119136831 A CN119136831 A CN 119136831A
Authority
CN
China
Prior art keywords
composition
csf
patient
seq
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380037559.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·费尔德豪斯
X·苗
C·王
Y·娄
Y·邹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Partner Therapy Ltd
Original Assignee
Partner Therapy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Partner Therapy Ltd filed Critical Partner Therapy Ltd
Publication of CN119136831A publication Critical patent/CN119136831A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202380037559.9A 2022-04-08 2023-03-28 长效粒细胞巨噬细胞-集落刺激因子 Pending CN119136831A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263329039P 2022-04-08 2022-04-08
US63/329,039 2022-04-08
PCT/US2023/065047 WO2023196747A1 (en) 2022-04-08 2023-03-28 Long-acting granulocyte macrophage-colony stimulating factor

Publications (1)

Publication Number Publication Date
CN119136831A true CN119136831A (zh) 2024-12-13

Family

ID=88243563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380037559.9A Pending CN119136831A (zh) 2022-04-08 2023-03-28 长效粒细胞巨噬细胞-集落刺激因子

Country Status (9)

Country Link
US (1) US20250230210A1 (https=)
EP (1) EP4504262A4 (https=)
JP (1) JP2025511929A (https=)
KR (1) KR20250004698A (https=)
CN (1) CN119136831A (https=)
AU (1) AU2023248440A1 (https=)
CA (1) CA3247715A1 (https=)
TW (1) TW202342089A (https=)
WO (1) WO2023196747A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr
CN118909139A (zh) * 2024-07-24 2024-11-08 广东壹加再生医学研究院有限公司 一种活化树突状细胞的分子、方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
HUE070957T2 (hu) * 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
CA3070253A1 (en) * 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
JP2023514972A (ja) * 2020-02-12 2023-04-12 ザ スクリプス リサーチ インスティテュート 長時間作用型ｇｍ－ｃｓｆおよび使用方法

Also Published As

Publication number Publication date
EP4504262A1 (en) 2025-02-12
CA3247715A1 (en) 2023-10-12
AU2023248440A1 (en) 2024-10-17
KR20250004698A (ko) 2025-01-08
WO2023196747A1 (en) 2023-10-12
EP4504262A4 (en) 2026-04-15
US20250230210A1 (en) 2025-07-17
JP2025511929A (ja) 2025-04-16
TW202342089A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
JP2026048634A (ja) 獣医学用ｉｇｇ ｆｃ変異体
CN107074928B (zh) 新型猫促红细胞生成素受体激动剂
KR102008136B1 (ko) Ｃｘ3ｃｒ1-결합 폴리펩타이드
RU2651776C2 (ru) Биспецифические антитела против cd3*cd19
KR20190140943A (ko) 항-cd33 항체 제제
RU2661087C2 (ru) Гибридная конструкция, включающая антигенсвязывающий фрагмент, специфичный к сывороточному альбумину, и эффекторный компонент, и способы ее получения
CN113166218B (zh) 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
US20250230210A1 (en) Long-acting granulocyte macrophage-colony stimulating factor
JP2023522029A (ja) イヌ科動物抗体バリアント
WO2020086406A2 (en) Anti-npr1 antibodies and uses thereof
AU2016344134A1 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
TW202003570A (zh) 抗trem-1抗體及其用途
US20220281939A1 (en) Modified tff2 polypeptides
JP2023055875A (ja) Ｈｉｖ融合体を標的とするポリペプチド
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
US20220372495A1 (en) Fusion polypeptides
US20240182535A1 (en) Granulocyte macrophage-colony stimulating factor mutants
CN116507355A (zh) 粒细胞巨噬细胞集落刺激因子突变体
JP2023553117A (ja) 顆粒球マクロファージコロニー刺激因子の製造
JP2024546726A (ja) 抗体－サイトカイン融合タンパク質及びその用途
WO2025186043A1 (en) Pharmaceutical formulation for anti-ccr8 antibodies
EP4426337A1 (en) Iga fc and igg fc tandem protein constructs
HK40120697A (zh) Il2突变蛋白及其用途
HK40066087A (zh) Cxcr4结合分子
KR20170027795A (ko) 항-사이토카인 항체의 동정을 위한 인간-유래 항-인간 il-20 항체 및 검정

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination